Literature DB >> 14633774

Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis.

Zhen-Yi Wang1.   

Abstract

Conventional treatment of acute leukemia involves the use of cytotoxic agents (chemotherapy), but other strategies have been explored. All-trans retinoic acid (ATRA) and arsenic have clearly been effective in the treatment of acute promyelocytic leukemia (APL), which creates the possibility that other types of acute leukemia can be conquered by selectively inducing differentiation and/or apoptosis. A great number of investigations have been performed to elucidate the mechanisms and search for effective agents in the treatment of other types of acute leukemia by these new strategies. Progress at the molecular level has been achieved in explaining the mechanisms of action of ATRA and arsenic compounds, and several new agents have emerged, although their clinical effectiveness remains to be confirmed. Mechanism-/gene-based targeted therapy and a combination of different strategies will improve the treatment of acute leukemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633774     DOI: 10.1182/asheducation-2003.1.1

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  12 in total

Review 1.  Biological screening of natural products and drug innovation in China.

Authors:  Ming-Wei Wang; Xiaojiang Hao; Kaixian Chen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

2.  Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide: Experience from a Tertiary Care Center in India.

Authors:  Karthik Udupa; Joseph Thomas; Chethana Babu Udupa; V S Binu; Prahlad Sharan
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-24       Impact factor: 0.900

3.  Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.

Authors:  Qinghang Meng; Zhimin Peng; Liang Chen; Jutong Si; Zhongyun Dong; Ying Xia
Journal:  Cancer Lett       Date:  2010-12-18       Impact factor: 8.679

4.  Tanshinone IIA activates calcium-dependent apoptosis signaling pathway in human hepatoma cells.

Authors:  Zhi-Kai Dai; Jiang-Ke Qin; Jiao-E Huang; Yong Luo; Qing Xu; Hai-Lu Zhao
Journal:  J Nat Med       Date:  2011-08-19       Impact factor: 2.343

Review 5.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

6.  Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells.

Authors:  Jing Wang; Xiujie Wang; Shu Jiang; Shulan Yuan; Ping Lin; Jie Zhang; Yanrong Lu; Qi Wang; Zhujuan Xiong; Yaying Wu; Jingjing Ren; Hongliang Yang
Journal:  J Neurooncol       Date:  2006-09-06       Impact factor: 4.130

Review 7.  Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

Authors:  Guang-Biao Zhou; Ji Zhang; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

Review 8.  Retinoic acid and arsenic for treating acute promyelocytic leukemia.

Authors:  Guang-Biao Zhou; Wei-Li Zhao; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  PLoS Med       Date:  2005-01       Impact factor: 11.069

9.  Effects of As2O3 nanoparticles on cell growth and apoptosis of NB4 cells.

Authors:  Xiaoyan Dong; Ning Ma; Mengmeng Liu; Ziling Liu
Journal:  Exp Ther Med       Date:  2015-07-23       Impact factor: 2.447

10.  Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation.

Authors:  Li Zhang; Qiu-Sheng Chen; Peng-Peng Xu; Ying Qian; Ai-Hua Wang; Dan Xiao; Yan Zhao; Yan Sheng; Xiang-Qin Wen; Wei-Li Zhao
Journal:  J Hematol Oncol       Date:  2014-10-01       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.